Study identifier:D5890L00014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A comparison of the efficacy of Symbicort® Single inhaler Therapy (Symbicort Turbuhaler® 160/4.5 mg 1 inhalation b.i.d. plus as-needed) and conventional best practice for the treatment of persistent asthma in adolescents and adults – a 26 weeks, randomised, open-label, parallel-group, multicentre study
asthma
Phase 3
No
Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy
All
1000
Interventional
12 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|